secwatch.observer — SEC 8-K summary
======================================

Issuer:     NIKA PHARMACEUTICALS, INC (NIKA)
CIK:        0001145604
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001826466-24-000056
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nika Pharmaceuticals acquires subsidiary and factory building valued at $2.05M; signs $958K supply agreement
--------------------------------------------------------------------------------

- Acquired 100% of Nika Pharmaceuticals, Ltd. from CEO Dimitar Savov for nominal 5,000 BGN (~$2,800).
- Acquisition includes beneficial ownership of a production building and land in Sofia valued at $2,045,209.
- Nika Europe, Ltd. signed a GMP vial production line supply agreement with Shanghai Marya for $957,670; down payment of $191,534 paid by CEO personally.
- Equipment delivery and installation expected by end of Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1145604/000182646624000056/0001826466-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1145604/000182646624000056/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001826466-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer